Skip to content
HomeMedia CenterPress releases PharmaceuticalsJohnson & Johnson Announces Landmark Agreement to Enable its COVID-19 Vaccine to be Manufactured and Made Available by an African Company for People Living in Africa

Johnson & Johnson Announces Landmark Agreement to Enable its COVID-19 Vaccine to be Manufactured and Made Available by an African Company for People Living in Africa

Aspen will manufacture and provide the Johnson & Johnson COVID-19 vaccine under its own brand name per the terms of agreement
Ensuring equitable, global access to COVID-19 vaccines has been a pillar of Johnson & Johnson’s response since the earliest days of the pandemic
The production of COVID-19 vaccines on multiple continents is critical to supporting an equitable response, controlling the pandemic, and improving long-term health security

Share Article
share to

NEW BRUNSWICK, NJ (March 8, 2022) – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the completion of a landmark agreement between Janssen Pharmaceuticals, Inc., and manufacturer Aspen SA Operations (Pty) Ltd, based in South Africa, to enable the first COVID-19 vaccine to be manufactured and made available by an African company for people living in Africa, with the goal of increasing COVID-19 vaccination rates across the continent.

Expanding global vaccination coverage is critically important to controlling the COVID-19 pandemic and reducing the risk of emergence of new SARS-CoV-2 variants. Currently, only about 12 percent of people in Africa are fully vaccinated, which is well below the World Health Organization’s target of 70 percent population coverage for all countries.

Our response to the COVID-19 pandemic has been guided by the conviction that unless everyone is safe, no one is safe, which is why we worked to develop and deliver a vaccine that can protect the health of everyone, everywhere.

“From the outset of this pandemic we aimed to develop a simple-to-use and accessible vaccine that could be transported around the world through standard vaccine distribution channels,” said Martin Fitchet, M.D., Head of Global Public Health, Johnson & Johnson, Cilag GmbH International. “We initiated clinical trials in all regions of the world to generate evidence across multiple geographies and diverse, at-risk populations and forged a strategic partnership with Aspen in Africa and others to manufacture our vaccine globally. We’re proud to take our long-standing collaboration with Aspen to the next level, to continue to address the COVID-19 threat and lay the groundwork for a healthier, more secure future for people in Africa.”

To date, Johnson & Johnson has shipped more than 200 million vaccine doses to Africa through a combination of our advance purchase agreements with the African Vaccine Acquisition Trust, South Africa and Gavi, the Vaccine Alliance, on behalf of the COVAX Facility, along with government donations. As one of our contract manufacturers since November 2020, Aspen has been a significant supplier within the Johnson & Johnson global network.

The agreement enables Aspen, using COVID-19 vaccine drug substance supplied by Johnson & Johnson, to produce Aspen-branded finished vaccine and make doses available to the public sector in Africa, including all 55 Member States of the African Union and key multilateral entities supporting Africa’s COVID-19 vaccination drive, inclusive of the African Vaccine Acquisition Trust (AVAT), and the COVAX Facility.

“With the conclusion of this agreement, our vision for Africa’s own vaccine has become a reality,” said Stephen Saad, Aspen Group Chief Executive. “This has been achieved through tremendous teamwork and collaboration between Johnson & Johnson and Aspen. Through this agreement and their earlier actions, Johnson & Johnson has demonstrated its commitment to our continent. Initially by choosing Aspen, located in Africa, as a core manufacturing partner, and then by showing resolve and dedication to a technical transfer process during the most stringent lockdown periods of the COVID outbreak.”

Johnson & Johnson’s Equitable Response to COVID-19
A commitment to global equity has guided the Company’s response since the beginning of the pandemic, starting with the decision to pursue a vaccine that can provide protection with a single dose and be easily stored and distributed with standard refrigeration globally, including in resource-limited, rural or remote settings.

Johnson & Johnson supported the development of its vaccine with a truly global and inclusive clinical research program that studied the vaccine across the U.S., Europe, Africa, Asia and Latin America as we sought to generate evidence across multiple geographies and diverse, at-risk populations, including in resource-limited settings. We complemented this by supporting a large-scale implementation study for our vaccine in South Africa. The “Sisonke” study made the Johnson & Johnson COVID-19 vaccine available to 500,000 frontline healthcare workers across the country.

In parallel, the Company forged a global supply network that included Aspen and partners in the U.S., Europe and India, and entered into advance purchase agreements with Gavi, on behalf of the COVAX Facility, and AVAT to supply 420 million vaccine doses to low- and middle-income countries (LMICs) through 2022.

“The urgency and necessity of developing and delivering our COVID-19 vaccine required our R&D teams to find new and exciting ways to use our novel vaccine technology to rapidly progress our science and maximize our impact for humanity,” said Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, Janssen Research & Development, LLC. “We have proudly contributed to protecting hundreds of millions of people from COVID-19. Our experiences will have major benefits for the future of vaccine development and Johnson & Johnson’s ongoing research and development programs as we continue to bring cutting-edge science to bear on complex health challenges.”

In 2021, Johnson & Johnson provided its vaccine globally at a not-for-profit price, and through its advance purchase agreements and country donations, shipped approximately 70% of its global vaccine supply to LMICs. The Company remains committed to ensuring its vaccine is accessible to people around the world and continues to advocate that governments with available doses follow the example of the U.S., European Union and others and immediately ramp up dose sharing, particularly through the COVAX Facility.

Johnson & Johnson has also pledged its support to the COVAX Humanitarian Buffer through an agreement with the U.S. Government and Gavi. This agreement enables access to our COVID-19 vaccine for the world’s most vulnerable people, such as those living in conflict zones and other humanitarian settings who are at risk of exclusion from traditional vaccination campaigns.

About the Johnson & Johnson COVID-19 Vaccine
The Johnson & Johnson COVID-19 vaccine has a robust profile in scientific, clinical and real-world studies, generating strong, persistent activity against SARS-CoV-2 and variants such as Delta and Omicron. The vaccine’s efficacy, both as a single dose and in boosted regimens, combined with its compatibility with standard refrigeration requirements, uniquely positions it for ease of deployment in any setting.

The Johnson & Johnson COVID-19 vaccine has an Emergency Use Listing (EUL) from the World Health Organization (WHO) and has been authorized in many other countries worldwide, including 50 countries in Africa. The vaccine is authorized by the U.S. Food and Drug Administration (FDA) through an Emergency Use Authorization (EUA), and has a Conditional Marketing Authorization from the European Commission for use across the European Union (EU).

On February 28, the European Medicines Agency approved an extension of the shelf-life of the Johnson & Johnson COVID-19 vaccine to 11 months when refrigerated at temperatures of 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit). On March 7, Johnson & Johnson confirmed that the U.S. FDA has extended the shelf-life of the Company’s vaccine from six months to nine months when stored at these same temperatures. These decisions are based on data from ongoing stability assessment studies. Johnson & Johnson has also submitted these data regarding the vaccine’s shelf-life to the WHO, and a decision is expected shortly.


About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology and Pulmonary Hypertension.

Learn more at Follow us at @JanssenUS and @JanssenGlobal. Janssen Research & Development, LLC, Janssen Pharmaceuticals Inc., and Cilag GmbH International are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

About Johnson & Johnson
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at Follow us at @JNJNews.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding an agreement with Aspen SA Operations (Pty) Ltd relating to the development, manufacture and distribution of the Johnson & Johnson COVID-19 vaccine. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Pharmaceuticals, Inc., the Janssen Pharmaceutical Companies, and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities of the agreement may not be realized or may take longer to realize than expected; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Report on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. None of Janssen Pharmaceuticals, Inc., the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.


Media Contacts:
Jake Sargent
+1 732-524-1090

Seema Kumar
+1 908-405-1144

Ronan Collins
+47 488-425-00

Investor Relations:
Raychel Kruper
+1 732-524-6164

You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.